Skip to main content
. 2016 Apr;101(4):474–481. doi: 10.3324/haematol.2015.136408

Figure 1.

Figure 1.

Outcomes based on intent-to-treat analysis. (A) Freedom from second failure (FF2F) and (B) overall survival (OS) of patients with first-relapsed or primary refractory Hodgkin lymphoma according to risk group. (C) FF2F and (D) OS of patients with primary refractory or unfavorable relapse (≥2 of the following risk factors at first relapse: relapse <12 months, stage III or IV at relapse, and/or relapse within previously irradiated sites). Median follow-up: 10.3 years.